World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0035641157
Reproduction Date:

Title: Metkefamide  
Author: World Heritage Encyclopedia
Language: English
Subject: Frakefamide, List of opioids, Kobret, 6β-Naltrexol-d4, Hemorphin
Collection: Amides, Analgesics, Opioid Peptides
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
Pharmacokinetic data
Bioavailability 30-35%[1]
Protein binding 44-49%[2]
Metabolism Hepatic[1]
Half-life ~60 minutes[3]
CAS number
66960-35-8 (acetate)
ATC code None
Chemical data
Formula C29H40N6O6S 
Mol. mass 600.730 g/mol

Metkefamide (synthetic opioid pentapeptide and derivative of [Met]enkephalin with the amino acid sequence Tyr-D-Ala-Gly-Phe-(N-Me)-Met-NH2.[4] It behaves as a potent agonist of the δ- and μ-opioid receptors with roughly equipotent affinity,[5][6] and also has similarly high affinity as well as subtype-selectivity for the κ3-opioid receptor.[7][8]

Despite its peptidic nature, upon systemic administration, metkefamide rapidly penetrates the blood-brain-barrier and disperses into the central nervous system where it produces potent, centrally-mediated analgesic effects,[9] of which have been shown to be dependent on activity at both the μ- and δ-opioid receptors.[6][10] In addition, on account of modifications to the N- and C-terminals, metkefamide is highly stable against proteolytic degradation relative to many other opioid peptides.[11][3] As an example, while its parent peptide, [Met]enkephalin, has an in vivo half-life of merely seconds, metkefamide has a half-life of nearly 60 minutes, and upon intramuscular administration, has been shown to provide pain relief that lasts for hours.[3]

Likely on account of its δ-opioid activity, clinical trials have found metkefamide to possess less of a tendency for producing many of the undesirable side effects usually associated with conventional opioids such as respiratory depression, tolerance, and physical dependence.[6][12] However, it has been shown to cause some additional side effects that are considered unusual for standard opioid analgesics like sensations of heaviness in the extremities and nasal congestion—though these were not considered to be particularly distressing[9]—and it has also been shown to raise the seizure threshold in animals.[13] In any case, clinical development was not further pursued after phase I clinical studies and metkefamide never reached the pharmaceutical market.[14][15][16]

See also


  1. ^ a b J S Davies; Royal Soc of Chem (8 November 2000). Amino Acids, Peptides and Proteins. Royal Society of Chemistry. p. 258.  
  2. ^ Oliver Kayser; Heribert Warzecha (13 June 2012). Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications. John Wiley & Sons. p. 346.  
  3. ^ a b c Vincent H. L. Lee (1991). Peptide and Protein Drug Delivery. CRC Press. p. 90.  
  4. ^ Dr. Ian Morton; Ian K. M. Morton; Judith M. Hall; Dr. Judith Hall (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 180.  
  5. ^ Burkhardt C, Frederickson RC, Pasternak GW (1982). "Metkephamid (Tyr-D-ala-Gly-Phe-N(Me)Met-NH2), a potent opioid peptide: receptor binding and analgesic properties". Peptides 3 (5): 869–71.  
  6. ^ a b c Frederickson RC, Smithwick EL, Shuman R, Bemis KG (February 1981). "Metkephamid, a systemically active analog of methionine enkephalin with potent opioid alpha-receptor activity". Science (New York, N.Y.) 211 (4482): 603–5.  
  7. ^ Linda M. Pullan; Jitendra Patel (1996). Neurotherapeutics: Emerging Strategies. Humana Press. p. 172.  
  8. ^ Clark JA, Liu L, Price M, Hersh B, Edelson M, Pasternak GW (November 1989). "Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype". The Journal of Pharmacology and Experimental Therapeutics 251 (2): 461–8.  
  9. ^ a b Calimlim JF, Wardell WM, Sriwatanakul K, Lasagna L, Cox C (June 1982). "Analgesic efficacy of parenteral metkephamid acetate in treatment of postoperative pain". Lancet 1 (8286): 1374–5.  
  10. ^ Hynes MD, Frederickson RC (1982). "Cross-tolerance studies distinguish morphine- and metkephamid-induced analgesia". Life Sciences 31 (12-13): 1201–4.  
  11. ^ Edith Mathiowitz; Donald E. Chickering; Claus-Michael Lehr (13 July 1999). Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development. CRC Press. p. 323.  
  12. ^ Stanley Stein (31 August 1990). Fundamentals of Protein Biotechnology. CRC Press. p. 17.  
  13. ^ Tortella FC, Robles LE, Holaday JW, Cowan A (1983). "A selective role for delta-receptors in the regulation of opioid-induced changes in seizure threshold". Life Sciences. 33 Suppl 1: 603–6.  
  14. ^ Denis M. Bailey (1 August 1987). Annual Reports in Medicinal Chemistry. Academic Press. p. 58.  
  15. ^ MaryLouise Embrey; Christine R. Hartel (1 August 1999). Drug Abuse and Drug Abuse Research (1991): The Third Triennial Report to Congress from the Secretary, Department of Health and Human Services. DIANE Publishing. p. 51.  
  16. ^ Dictionary of Pharmacological Agents Volume 2. CRC Press. p. 1343.  

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.